Showing 1 - 3 results of 3 for search 'Ana Maria Arance', query time: 0.02s Refine Results
  1. 1
    194 Characterization of the pharmacodynamic activity of CLN-619, an anti-MICA/B monoclonal antibody, in patients from an ongoing Phase 1 trial

    194 Characterization of the pharmacodynamic activity of CLN-619, an anti-MICA/B monoclonal antibody, in patients from an ongoing Phase 1 trial by Victor Moreno, Ignacio Melero, Michael Millward, Tracy Liu, Rafał Stec, Erika Hamilton, Ana Maria Arance, Jennifer S Michaelson, Laura Liu, Alexander I Spira, Judy S Wang, Irina M Shapiro, Kerry A Whalen, Jeffrey A Jones

    Published 2023-11-01
    Article
  2. 2
    770 ADU-1604, a novel CTLA-4 blocking antibody modulates pharmacodynamic markers in PD1 relapse/refractory melanoma patients

    770 ADU-1604, a novel CTLA-4 blocking antibody modulates pharmacodynamic markers in PD1 relapse/refractory melanoma patients by Caroline Robert, Ivan Marquez-Rodas, Michele Maio, Vanna Chiarion-Sileni, Piotr Rutkowski, Hans Van Eenennaam, Julien Villaudy, Jessica Kundapur, Ana Maria Arance, Alexander Eggermont, Guillemo De Velasco Oria de Rueda, Laura Lassouw-Polman

    Published 2023-11-01
    Article
  3. 3
    Long-term real-world experience with ipilimumab and non-ipilimumab therapies in advanced melanoma: the IMAGE study

    Long-term real-world experience with ipilimumab and non-ipilimumab therapies in advanced melanoma: the IMAGE study by Stéphane Dalle, Laurent Mortier, Pippa Corrie, Michal Lotem, Ruth Board, Ana María Arance, Frank Meiss, Patrick Terheyden, Ralf Gutzmer, Brian Buysse, Kelly Oh, Jane Brokaw, T. Kim Le, Susan D. Mathias, Julie Scotto, Jennifer Lord-Bessen, Andriy Moshyk, Srividya Kotapati, Mark R. Middleton

    Published 2021-05-01
    Get full text
    Article

Search Tools: